Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varenicline - Oyster Point Pharmaceuticals

Next Previous
Drug Profile

Varenicline - Oyster Point Pharmaceuticals

Alternative Names: OC-01; OC-01 nasal spray; TYRVAYA; TYRVAYA®

Latest Information Update: 30 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oyster Point Pharmaceuticals
  • Developer Corxel Pharmaceuticals; Oyster Point Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Antivirals; Azabicyclo compounds; Benzazepines; Bridged-ring heterocyclic compounds; Eye disorder therapies; Pyrazines; Quinoxalines; Small molecules; Smoking cessation therapies
  • Mechanism of Action Alpha4 beta2 nicotinic receptor agonists; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dry eyes
  • Phase II Neurotrophic keratopathy
  • Preclinical COVID 2019 infections

Most Recent Events

  • 11 Dec 2024 Varenicline licensed to Grand Pharmaceutical Group in the China
  • 01 Nov 2024 Registered for Dry eyes in China (Intranasal)
  • 28 Oct 2024 Ji Xing Pharmaceuticals is now called Corxel Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top